The COVID pandemic showed lack of preparedness in many public health areas all over Europe. One such gap – often overlooked – is the lack of tools to rapidly conduct clinical studies on new vaccines. This gap has been closed now by Vaccelerate – an academic consortium funded by the EU commission and charged with accelerating phases 1, 2 and 3 of vaccine trials. The consortium is organized by Prof. Oliver Cornely at the University of Cologne, who explains how Vaccelerate works.
View all comments